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Abstract 
Review on RANBP2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: ADANE, ANE1, NUP358 
HGNC (Hugo): RANBP2 
Location: 2q12.3 
Note 
The human RANBP2 gene lies within a 
recombination "hot spot" genomic region on Chr 
2q11-q13 (Krebber et al., 1997) as part of a gene 
"cluster" that contains the partially duplicated gene 
RANBP2L1, containing the RANBP2 5' gene 
portion (Nothwang et al., 1998). 
DNA/RNA 
Note 
RANBP2 is an essential gene and RANBP2-null 
mice display early embryonic lethality (Aslanukov et 
al., 2006; Dawlaty et al., 2008). A single RANBP2 
hypomorphic allele is, however, sufficient for 
viability. 
Description 
The human RANBP2 gene comprises 31 exons and 
gives rise to one major mRNA encoding the 
RANBP2 protein, with at least 8 less represented 
alternative splicing variants (AceView; NCBI; 
GeneCards). 
Transcription 
RANBP2 mRNA transcription is widespread in 
many though not all tissues (Fauser et al., 2001). In 
the mouse genome, the Ranbp2 promoter region lies 
in a CpG island, typical of "housekeeping" gene 
promoters and potentially subjected to epigenetic 
regulation. In silico analysis of the human RANBP2 
gene promoter has identified potential binding sites 
for cell cycle- and cell proliferation-dependent 
transcription factors, some validated in chromatin 
immunoprecipitation (ChIP) assays (e.g., c-Fos, AP1 
and others) (GeneCards).  
Binding sites for tissue-specific factors are also 
present, and RANBP2 mRNA transcript and protein 
product are highly expressed in certain tissues and 
cell types, e.g. neuronal cells (Fauser et al., 2001).  
Serial analysis of gene expression (SAGE) depicted 
aberrant up-regulation of RANBP2 in certain 
cancers, e.g. multiple myeloma (Felix et al., 2009). 
Protein 
Note 
Biological overview: The RAN-binding protein 2 
(RANBP2) or Nucleoporin 358 (NUP358, 
nucleoporin of 358 kDa) is the largest component of 
nuclear pore complexes (NPCs). The latter are 
highly complex structures composed of several 
orderly assembled proteins, called nucleoporins 
(NUPs), that represent gateways across the nuclear  
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envelope (NE) for the exchange of macromolecules 
between the nucleus and the cytoplasm. This 
exchange is critical to many essential processes, e.g., 
DNA replication, DNA repair, DNA damage 
response, establishment of functional chromatin 
domains, replication checkpoint, transcriptional and 
epigenetic regulation of genes and genome function, 
mitotic entry.  
The RANBP2 nucleoporin is specific of higher 
eukaryotes and has a multimodular structure (Wu et 
al., 1995; Yokoyama et al., 1995; Wilken et al., 
1995).  
It is unique among NUPs in that it is endowed with 
E3-type ligase activity for SUMO (small ubiquitin-
related modifier) peptides (Pichler et al., 2002). This 
will be discussed in more depth below.  
RANBP2 operates in two major groups of cellular 
processes:  
- NPC- and NE-dependent processes ensuring 
nuclear functions in interphase (e.g., nuclear 
positioning, recruitment of motor proteins at the NE, 
centrosome anchoring to the NE, import and export 
of macromolecules in and out of the nucleus, 
including transcription and regulatory factors 
governing genome function); and  
- cell division events (NE breakdown, centrosome 
migration, assembly of the mitotic apparatus, 
chromosome segregation).  
In many of these processes, RANBP2 stimulates the 
conjugation of SUMO peptides (SUMO-1 to -4) to 
various target proteins at specific intracellular sites: 
the nuclear rim in interphase, and microtubules 
(MTs) as well as kinetochores (KTs) in mitosis. 
SUMO conjugation is emerging as a protein post-
translational modification that modulates the 
localization and interactions of several proteins 
(reviewed by Lomelí and Vázquez, 2011; Flotho and 
Melchior, 2013).  
The protein-modifying and transport-regulating 
activities of RANBP2 target specific substrates in 
many tissues and cell types. As a result, RANBP2 
acts as a cell context-dependent pleiotropic protein 
in a variety of physiological and pathological 
processes, including tumor suppression, 
neuroprotection and familial necrotic 
encephalopathy. 
Description 
The human RANBP2 protein is composed of 3224 
aminoacidic residues, with a molecular weight of 
358 KDa, hence its name (Wu et al., 1995; 
Yokoyama et al., 1995). The alternative name 
RANBP2 derives from the presence of four RAN-
binding domains (RBD), through which it binds the 
GTPase RAN. RANBP2 contains several more 
structural domains:  
- An N-terminal leucine-rich region anchors 
RANBP2 to the NPC. This region is also implicated  
in binding interphase microtubules (MTs) and 
regulating their dynamics (Joseph and Dasso, 2008).  
The structure of this region reveals an alpha-helical 
domain harboring three central tetratricopeptide 
repeats (TPRs) capable to bind single-stranded RNA 
in solution and thought to contribute to messenger 
ribonucleoprotein (mRNP) remodeling at the 
cytoplasmic face of the NPC (Kassube et al., 2012). 
- Four RAN binding domains (RBD1-4) 
(Yokoyama et al., 1995), 46-60% identical to the 
prototype RAN-binding domain (Pfam) in the first 
cloned RAN-binding partner, RANBP1 (Bressan et 
al., 1991; Coutavas et al., 1993).  
The RBDs act as coactivators of GTP hydrolysis on 
RAN with a dual purpose: a) to assist nuclear protein 
import, by preventing the accumulation of RANGTP 
at the NPC cytoplasmic side and avoid that 
RANGTP prematurely dissociates import complexes 
while traversing the NPC to reach the nucleus 
(Yaseen and Blobel, 1999a); b) to facilitate the 
export of nuclear cargos by assisting the dissociation 
of RANGTP from exportin-cargo complexes 
(Bernad et al., 2004). 
- Eight zinc-finger motifs (Cys2-Cys2 type) in the 
central portion of RANBP2; they provide a binding 
platform for exportin-1/CRM1 (Singh et al., 1999) 
and help CRM1 recycling into the nucleus (Bernad 
et al., 2004). These motifs can also interact with 
RanGDP (Yaseen and Blobel, 1999a). 
- Phenylalanine-glycine (FG) and FxFG repeats 
(the nucleoporin "signature" motif; x is any 
aminoacid) present on the fibril-like structures 
projecting from the NPC into the cytoplasm.  
These repeats provide multiple binding sites for 
nuclear transport receptors (karyopherin beta/ 
importin beta and exportin-1/CRM1. The interaction 
of FG-rich fibrils with transport vectors facilitates 
their passage across the NPC.  
- A domain endowed with SUMO E3 ligase 
activity, the first enzymatic activity identified for 
RANBP2 (Pichler et al., 2002), residing between 
RBDs 3 and 4, that regulates sumoylation of target 
proteins (more detail below).  
- A C-terminal domain with peptidyl-prolyl 
isomerase activity, the second enzymatic activity 
ascribed to RANBP2 (Lin et al., 2013). 
- A cyclophilin A-like domain, harbouring an active 
site cavity that facilitates the binding to the HIV-1 
capsid proteins during viral infection (Lin et al., 
2013). 
Thus far, the SUMO E3 ligase domain, two RBDs, 
the N-terminal TPR domain and the C-terminal 
domain have been crystallized and structurally 
characterized (Vetter et al., 1999; Reverter and 
Lima, 2005; Geyer et al., 2005; Kassube et al., 2012; 
Lin et al., 2013). 
The SUMO E3 ligase activity of RANBP2 and the 
RANBP2/RANGAP1*SUMO1/Ubc9 (RRSU) 
complex 
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In addition to binding RAN, RANBP2 stably 
associates with the RAN GTPase-activating protein 
1 (RANGAP1) (Mahajan et al., 1997; Saitoh et al., 
1997; Matunis et al., 1998; Swaminathan et al., 
2004) throughout the cell cycle.  
The interaction requires SUMO-1 conjugation to 
RANGAP1 (Matunis et al., 1996; Mahajan et al., 
1997) and the presence of the SUMO ubiquitin-like-
conjugating Ubc9 enzyme (Zhang et al., 2002; Zhu 
et al., 2006), an E2 enzyme that transfers SUMO 
peptides to SUMO chains, analogous to enzymes 
acting in the ubiquitination cascade.  
RANBP2 is possibly the most abundant SUMO E3 
ligase in the cell, and as such has a prominent role in 
SUMO modification of proteins. Most RANBP2-
dependent functions are likely mediated by its 
activity in SUMO conjugation of target proteins.  
The RANBP2 SUMO E3 ligase domain lacks 
homology to other known SUMO or ubiquitin E3 
ligases (Pichler et al., 2004). It is characterized by 
two 50 aminoacid-long internal repeats, IR1 and IR2 
(43% identical), separated by a 20 aminoacid-long 
linker. Both IR1 and IR2 can bind to Ubc9 and 
catalyze sumoylation of substrates in vitro, though 
IR2 has lower affinity for Ubc9 than IR1 (Pichler et 
al., 2004; Tatham et al., 2005). 
RANBP2 is quantitatively engaged in complexes 
with sumoylated RANGAP1 and Ubc9. This binding 
requires RANBP2's IR1 and the SUMO-interaction 
motif SIM1, as well as Ubc9. Once IR1 and SIM1 
are occupied by RanGAP1*SUMO1 and Ubc9, the 
E3 ligase activity depends on IR2 (Werner et al., 
2012).  
In that sense, the entire RANBP2/RANGAP1-
SUMO complex (called RRSU complex) is viewed 
as a multisubunit SUMO ligase.  
Indeed, RRSU effectively sumoylates the 
physiological substrate Borealin in vitro (Klein et al., 
2009), whereas free RANBP2 does not (Werner et 
al., 2012).  
After NPC disassembly at NEB, RANBP2 remains 
associated with RANGAP1-SUMO1 and Ubc9 
(Swaminathan et al., 2004); RRSU associates with 
the mitotic spindle and a fraction is recruited to KTs 
after MTs attach to them (Joseph et al., 2002; Joseph 
et al., 2004). 
Localisation 
Intracellular localization: In interphase cells, 
RANBP2 localizes at the cytoplasmic face of the 
NPCs (Wu et al., 1995; Yokoyama et al., 1995; 
Wilken et al., 1995; Walther et al., 2002): RANBP2-
containing filaments are anchored to the NPC via 
interaction with a complex of nucleoporins 
containing Nup214 and Nup88 (Bernad et al., 2004) 
and project into the cytoplasm.  
Joseph et al. (2002 and 2004) first reported that, at 
the onset of mitosis, when the NE breaks down and 
NPCs disassemble, RANBP2 localizes to the 
microtubules (MTs) of the forming mitotic spindle, 
with an accumulation at poles; a fraction is recruited 
to chromosomal KTs when the latter become 
attached to MTs (Figure 2, bottom row). This 
localization underlies RANBP2's mitotic functions 
(see below). In early telophase RANBP2 is recruited 
back around chromatin of the reforming nuclei as the 
NE and NPCs reorganize. 
Function 
RANBP2 in interphase nucleocytoplasmic 
transport 
As anticipated above, RANBP2 localization at 
cytoplasmic fibrils emanating from the NPC 
underlies its function in nucleocytoplasmic 
transport. 
- Nuclear protein import  
RANBP2 serves as a docking site for import 
complexes (the latter are of two main types: either 
composed of importin vectors interacting with 
proteins marked by a nuclear localization signal, 
NLS, or composed of transportin bound to 
ribonucleoproteins marked by the so-called M9 
signal sequence, originally described in hnRNPs).  
The docking of import complex at RANBP2 
cytoplasmic fibrils of the NPC aids the earliest step 
in nuclear import (Melchior et al., 1995; Delphin et 
al., 1997; Mahajan et al., 1997; Yaseen and Blobel, 
1999b). RANBP2 itself does not directly participate 
in import, but facilitates it. In RANBP2-depleted 
HeLa cells, in vivo nuclear import by either Importin 
alpha/beta (Hutten et al., 2008) or transportin 
(Hutten et al., 2009) still occurs, but at substantially 
reduced rates. 
In a screening for nuclear proteins that accumulate in 
the cytoplasm upon RANBP2 depletion, Wälde and 
coworkers (2012) have also identified direct 
RANBP2 interactors: they found that an N-terminal 
fragment of RANBP2, harboring the NPC-binding 
domain, three FG motifs and RBD1, was sufficient 
to promote protein import, while neither the 
interaction with RANGAP1 nor the SUMO E3 ligase 
activity were required (Wälde et al., 2012). This is 
consistent with functional mapping data from 
Hamada and coworkers (2011) using various 
RANBP2-derived regions to complement RANBP2 
knockout MEF cells, in which the RANBP2 N-
terminal fragment restored import to RANBP2-null 
cells; the authors demonstrated a crucial role of this 
domain in aiding the recycling of RAN and importin 
beta complexes for nuclear import (Hamada et al., 
2011). 
In summary, RANBP2 aids nuclear import by at 
least two mechanisms: i) by "capturing" transport 
receptors through the FG-repeats, it conveys them 
towards the NPC and reduces the effective 
concentration of import receptors required for 
efficient transport, while ii) by interacting with 
selected cargos in a receptor-independent manner, 
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through the RANBP2 N-ter domain, it increases the 
overall efficiency of nuclear import.  
Interestingly, RANBP2 is also implicated in the 
nuclear delivery and integration of certain human 
viruses, including Herpes simplex (Copeland et al., 
2009) and immunodeficiency virus-1 (HIV-1) 
(Zhang et al., 2010; Ocwieja et al., 2011; Schaller et 
al., 2011). 
- Nuclear export 
RANBP2 also plays roles in mRNA export. 
Poly(A)+ mRNA accumulates in nuclei of 
RANBP2-null MEFs (Hamada et al., 2011), 
although the intracellular distribution of poly(A)+ 
mRNA is not affected in RANBP2 hypomorphic 
mice-derived MEF cells (Dawlaty et al., 2008): thus, 
mRNA export requires RANBP2, but can proceed, 
albeit being impaired, in the presence of significantly 
decreased abundance. These data suggest that 
RANBP2 facilitates the export pathway, yet is not an 
indispensable component.  
Overall, RANBP2 affects the rate of nucleo-
cytoplasmic transport of many proteins, including 
transcriptional and epigenetic factors. The latter are 
often mislocalized in tumor cells and in other cellular 
contexts in which RANBP2 expression is altered, 
with a global impact on genome functions. An 
emerging concept is that tumor cells exploit specific 
properties of NUPs to deregulate gene transcription, 
chromatin boundaries and essential transport-
dependent regulatory circuits (Xu and Powers, 2009; 
Köhler and Hurt, 2010). 
Structural functions at the nuclear rim and NPCs 
RANBP2 has structural roles at the NE besides 
nuclear transport proper. The development of in situ 
SUMOylation assays has revealed that both the 
nuclear rim and PML nuclear bodies are major sites 
of SUMOylation; RANBP2 inactivation abolished 
SUMOylation processes along the nuclear rim and 
reduced the number of PML bodies, while not 
affecting the nuclear lamina (Saitoh et al., 2006). The 
loss of nuclear PML bodies has been observed in 
tumorigenesis, particularly in colon cancer. Satow et 
al. (2012) reported that β-catenin overexpression 
disrupts PML bodies in colon cancer cell lines and 
inhibits RANBP2-dependent SUMOylation of 
specific PML-associated proteins. The data suggest 
that RANBP2 is required for SUMOylation of 
proteins associated with the formation of particular 
subnuclear structures, the loss of which impinges on 
nuclear functions in cancer cells.  
RANBP2 also recruits motor proteins at the NE to 
regulate NE breakdown at the onset of mitosis. 
Through its zinc finger domain, RANBP2 binds the 
COPI coatomer complex, which coats the Golgi 
vesicles and contributes to membrane remodelling at 
the Golgi; the RANBP2-derived zinc finger domain 
alone dominantly interferes with COPI recruitment 
to the nuclear rim and inhibits NE breakdown 
(Prunuske et al., 2006). Interestingly, RANBP2 acts 
cooperatively with Nup153, the most nuclear of the 
NUPs, which contains a distinct zinc finger domain, 
in coordinating NE breakdown.  
RANBP2 also binds to BICD2 (homologous to 
Drosophila Bicaudal D), an adaptor between motor 
proteins and their cargo, and recruits BICD2 to 
NPCs in the G2 phase of the cell cycle (Splinter et 
al., 2010). BICD2 in turn regulates dynein-dynactin 
motor complexes at NPCs, and thus centrosome 
tethering to the NE prior to mitotic entry. BIC2 is 
also required for the antagonistic activity of kinesin-
1, which pushes centrosomes apart. The balance 
between dynein and kinesin-1 opposite activities 
governs centrosomal positioning, and hence sites 
where centrosomes will nucleate the spindle MTs to 
form asters and later spindle poles; RANBP2 
recruitment of BICD2 to the NPCs just before NE 
breakdown represents a most upstream step in this 
cascade of events.  
A specialized version of this process takes place in 
radial glial progenitors (RGPs), from which neurons, 
glia, and brain adult stem cells originate. RGP nuclei 
migrate basally during G1, then apically during G2 
via dynein, and eventually divide at the ventricular 
surface. Hu et al. (2013) discovered that apical 
nuclear migration requires dynein recruitment at 
NPCs by two cooperating G2-specific mechanisms: 
the "RanBP2-BicD2" pathway acts first, and 
"Nup133-CENP-F" operates sequentially. This work 
identifies spatially regulated mechanisms, implying 
that only restricted regions of neurogenic tissues are 
permissive for mitosis: in this context, RANBP2 is 
essential for dynein control of apical nuclear 
migration, nuclear membrane remodelling and 
centrosome dynamics prior to mitosis.  
Cell differentiation-associated functions 
The NPC is not a static transport gate and undergoes 
dynamic remodelling during differentiation. In 
myogenic differentiation, myoblasts fuse to form 
syncithial myotubes. By atomic force microscopy, 
NPCs have been found to undergo structural 
differences during C2C12 myogenic cell 
differentiation from myoblasts to myotubes, parallel 
to an increased amount of RanBP2 at NPCs (Asally 
et al., 2011). siRNA-mediated depletion of RanBP2 
in myoblasts suppresses differentiation to myotubes. 
Thus, RanBP2 is required for NPC remodelling in 
myogenesis, suggesting that a re-adaptation of 
transport mechanisms, and of the gateways through 
which these take place, is required as myotubes fuse 
and many nuclei become immersed in a common 
cytoplasm. 
RANBP2 can carry out more specialized functions 
in a tissue-specific manner. RANBP2 is highly 
abundantly expressed in the vertebrate retina. Its 
cyclophilin domain (which led Ferreira et al., (1996) 
to classify RANBP2 as Type-II cyclophilin), and the 
RB4 domain, interacts with opsin, a retinal 
transmembrane protein; the RBD4 and cyclophilin 
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domains are therefore proposed to act as a functional 
"supradomain" with a chaperone function for opsin 
in the retina. Along with this chaperone function, 
RANBP2 associates through its cyclophilin-like 
domain with subunits of the 19S regulatory complex 
of the 26S proteasome in the neuroretina (Ferreira et 
al., 1998), and thus contributes to control the 
stability of proteins that it "chaperones" in the retina.  
Related to RANBP2 transport functions but 
independent from them, Cai et al., (2001) identified 
a novel domain between RBD2 and RBD3 capable 
of direct association with two MT-based kinesin 
motors, KIF5B and KIF5C, in neuronal cells. 
Preventing the interaction of the RANBP2 kinesin-
binding domain (KBD) with KIF5B / KIF5C in 
neuronal cells caused perinuclear clustering of 
mitochondria, deficits in mitochondrial membrane 
potential and cell shrinkage (Cho et al., 2007): thus 
RANBP2 modulates kinesin-dependent 
mitochondria transport and function. The RBD2, 
KBD and RBD3 domains of RANBP2 are proposed 
to constitute a tripartite domain (R2KR3), 
modulating mitochondrial transport via kinesin 
subtypes in subsets of neuroretinal cells (Patil et al., 
2013).Aslanukov et al. (2006) discovered yet 
another association of RANBP2, via its leucine-rich 
domain, with Cox11, a mitochondrial 
metallochaperone, and HKI (hexokinase type I), 
defined as the "pacemaker" of glycolysis. Cox11 
inhibits HKI activity, but RANBP2 suppresses this 
inhibition. Consequently, RANBP2 
haploinsufficient mice show markedly decreased 
HKI and ATP levels in the central nervous system, 
with deficits in growth rates and glucose catabolism 
(Aslanukov et al., 2006). These mice also show 
absent or severely reduced cell death response to 
light-induced oxidative stress in the retina (Cho et 
al., 2010). RANBP2 cell type-conditional mice 
models, selectively lacking RANBP2 either in rod or 
in cone photoreceptors (Cho et al., 2013), showed 
that RANBP2 ablation in cone photoreceptors 
promoted their non-apoptotic death, while rod 
photoreceptors underwent cone-dependent non-
autonomous apoptosis. Thus, RANBP2 modulates 
cell type-specific and distinct pathways of cell death 
- a key feature of neurodegenerative diseases.  
Mitosis 
- Mitotic spindle organization 
Chromosome segregation at mitosis is crucial to the 
maintenance of genomic stability, a process often 
disrupted in cancer. A role of RANBP2 in 
chromosome segregation was first suggested by the 
finding that RANBP2 accumulates at the mitotic 
spindle in prometaphase, and in part at KTs upon MT 
attachment (Joseph et al., 2002; see figure 2); at these 
sites RANBP2 remains associated in complex with 
RANGAP1-SUMO1, suggesting that some of its 
functions entail RANGTP hydrolysis at specific 
mitotic sites.  
In RNAi-based studies in human cells, RANBP2 
down-regulation caused multipolar spindles, with 
supernumerary poles lacking centrioles (hence 
suggestive of MT dysfunction) as well as defects in 
chromosome congression and segregation (Salina et 
al., 2003; Joseph et al., 2004; Klein et al., 2009; 
Hashizume et al., 2013). Consistent findings in 
Caenorhabditis elegans embryos (Askjaer et al., 
2002) suggest that mitotic functions of RANBP2 are 
conserved across species in which this protein is 
present.  
- Mitotic microtubule-kinetochore interactions 
Further studies showed that RANBP2 depletion 
resulted in aberrant KT morphology, associated with 
mis-localization of RANGAP1 and other KT 
proteins, e.g. Mad1, Mad2, Zw10, Mis12, CENP-A, 
CENP-E, CENP-F and dynein; RANBP2 depletion 
also caused lengthened prometaphase duration and 
chromosome misalignment at metaphase, but the 
simultaneous depletion of RANBP2 and either Mad1 
(Salina et al., 2003) or Mad2 (Joseph et al., 2004), 
two major spindle assembly checkpoint (SAC) 
regulators, restored normal prometaphase duration; 
these findings suggest that RANBP2 depletion-
dependent abnormalities activate the SAC. 
Interestingly, RANBP2 depletion yields unstable 
KT-MT interactions, suggesting that the 
concentration of RSSU complex at MT-attached 
KTs contributes to the functional connections 
between the spindle and chromosomes prior to 
chromosome segregation (Joseph et al., 2004). In 
conditions under which RSSU targeting to KTs was 
prevented, discrete attachments between MTs and 
KTs were not maintained, yielding high rates of 
chromosome mis-segregation (Salina et al., 2003; 
Joseph et al., 2004; Arnaoutov et al., 2005). Indeed, 
RANBP2 hypomorphic mice develop severe 
aneuploidy (Dawlaty et al., 2008). 
RSSU targeting to KTs is highly regulated in human 
cells and requires i) MT attachment to KTs, and ii) 
proteins that stabilize MT interaction with KTs, e.g. 
Hec1/Ndc80 and Nuf2 (Joseph et al., 2004). 
There is therefore a functional cross-talk between 
proteins that regulate MT/KT interactions, and 
RSSU recruitment to KTs, which in turn reinforces 
these interactions. Interestingly, CRM1 is required 
for the RSSU complex recruitment to KTs 
(Arnaoutov et al., 2005) while importin beta 
overexpression inhibits it (Roscioli et al., 2012).  
However, neither endogenous RANBP2, nor GFP-
tagged RANBP2 constructs, localize to KTs in 
MEFs (Hamada et al., 2011). Some cell cycle 
checkpoints are not yet fully proficient in embryonic 
cell cycles and some of their regulatory mechanisms 
may diverge from those operating in somatic cells.  
It is worth noting that cells subjected to extended 
RANBP2 RNAi for longer times eventually escape 
the mitotic arrest with defective MT/KT 
connections, originating multinucleated cells and/or 
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citokynesis defects (intracellular bridges) followed 
by cell death (Salina et al., 2003; Joseph et al., 2004). 
In terms of cancer prognosis, these data suggest that 
a very narrow threshold, probably modulated by the 
genetic background of the cells, defines whether 
defective RANBP2 expression is pro-tumorigenic 
(by inducing genetic instability in cells that remain 
viable) or anti-tumorigenic (by preventing normal 
cell division altogether and inducing the death of the 
severely aberrant cell products).  
Regulation of the SUMO conjugation pathway in 
mitosis 
MEFs with reduced RANBP2 levels are viable and 
display no overt nuclear transport abnormalities 
compared to wild-type, yet develop severe 
aneuploidy associated with chromosome segregation 
defects, including anaphase bridges (Dawlaty et al., 
2008). Chromatin bridges in anaphase are typical of 
cells in which DNA decatenation is impaired by 
mutation or inhibition of topoisomerase II alpha 
(Topo IIa) (Bhat et al., 1996).  
Studies in S. cerevisiae (Takahashi et al., 2006), 
Xenopus egg extracts (Azuma et al., 2003) and 
human cells have shown that Topo IIa is subjected to 
sumoylation (Azuma et al., 2003; Azuma et al., 
2005; Mao et al., 2000). Indeed, Dawlaty and 
coworkers observed that i) RANBP2 hypomorphic 
MEFs fail to accumulate Topo IIa at inner 
centromeres in mitosis, and ii) RANBP2 SUMO E3 
ligase activity is required for Topo IIa SUMO 
conjugation and inner centromere targeting, to 
enable decatenation of sister centromeres prior to 
anaphase onset (Dawlaty et al., 2008). 
RANBP2 also associates with the chromosomal 
passenger complex (CPC) during mitosis and 
stimulates sumoylation of Borealin (Klein et al., 
2009); this, however, affects neither CPC assembly 
nor its localization; RANBP2-dependent Borealin 
SUMOylation might be required for CPC interaction 
with an as yet unidentified protein(s) at centromeres 
(Klein et al., 2009).  
RANBP2 in cell viability 
As remarked, RANBP2 inactivation causes early 
embryonic lethality (Aslanukov et al., 2006; 
Dawlaty et al., 2008). Hamada and coworkers (2011) 
studied mitotic cell viability using a Cre-mediated 
RANBP2 conditional knockout approach. The 
incidence of chromosome missegregation was 100% 
for RANBP2-null MEFs, yet these cells did not die 
during faulty mitosis and rarely died during the next 
12 hours after mitotic exit, suggesting that the 
mitotic errors caused RANBP2 knock-out are not the 
primary cause of cell death (Hamada et al., 2011). 
Rescue experiments, expressing various RANBP2 
portions in a RANBP2-null background, revealed 
that a short N-terminal fragment corrected transport 
defects and restored cell viability, suggesting 
prominent NPC dysfunction, rather than mitotic 
failure, as the cause of cell death (Hamada et al., 
2011). By contrast, RANBP2 siRNA-silenced HeLa 
cells underwent prolonged metaphase followed by 
mitotic catastrophe in live cell imaging (Hashizume 
et al., 2013); the use of a fluorescently-tagged import 
reporter demonstrated that, under these conditions, 
RANBP2-depletion-induced mitotic death is not a 
side effect of failed nuclear import. The discrepancy 
between these models remains to be explained. 
Homology 
RANBP2 is conserved among metazoa but absent in 
Saccharomyces cerevisiae. 
Mutations 
Note 
An autosomal dominant mutation of RANBP2 
(1880C-->T, yielding the Thr585Met missense 
mutation in the leucine-rich domain required for 
binding to both the NPC and to MTs) has been 
identified in the familial predisposition to acute 
necrotizing encephalopathy (ANE), arising in 
otherwise healthy children after common viral 
infections, such as influenza (Neilson et al., 2009; 
Loh and Appleton, 2010). 
Fusions of the RANBP2 gene with the gene 
encoding anaplastic lymphoma kinase (ALK) are 
associated with inflammatory myofibroblastic 
tumors (see below).  
RANBP2 mutants (i.e. point mutations or deletion 
mutants) have been engineered in several 
laboratories to study the role of different domains in 
various cellular processes. 
Implicated in 
Various cancers 
Note 
RANBP2 is implicated in many cancer types. It is 
difficult to draw a single unifying mechanism, yet 
two recurrent features are worth noting:  
a) the SUMO ligase and SUMO-stabilizing activity 
of RANBP2 targets many mitotic factors, as 
explained above, which can contribute to genetic 
instability and tumorigenesis when dysregulated 
(e.g., RANGAP1 and hence the functional state of 
RAN at KTs, Topo II, Borealin). Mouse models 
created by crossing RANBP2 hypomorphic 
(RANBP2H) and null (RANBP2-) alleles, 
displaying gradual degrees of RANBP2 
insufficiency, are prone to carcinogen-induced and 
spontaneous tumors: the incidence of skin tumors 
dramatically increased in mice with reduced 
compared to wild-type RANBP2 expression and 
lung adenocarcinomas developed in virtually all 
insufficient mice (Dawlaty et al., 2008).  
b) generally, a striking link exists between some 
NUPs, their propensity to undergo translocation and 
fusion with other gene partners and neoplastic 
diseases (reviewed in Köhler and Hurt, 2010). 
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RANBP2 shares this tendency with some other 
NUPs: residing in a chromosomal recombination 
"hot spot", is involved in several instances of 
translocation; signalling molecules involved in the 
resulting fusion protein become aberrantly 
concentrated at the NE, with tumorigenic 
consequences (see below). 
Inflammatory myofibroblastic tumors 
Note 
RANBP2 is implicated in a subset of inflammatory 
myofibroblastic tumors (IMT), rare soft tissue 
tumors involving mesenchymal cell types, with a 
prominent inflammatory component. IMTs rarely 
metastasize, yet often recur rapidly with fatal 
outcomes in some cases. Some 50% of IMTs harbor 
rearrangements of the ALK gene (encoding the 
anaplastic lymphoma kinase ALK), located at 2p23, 
with diverse partners, and overexpress the ALK 
protein, mostly in the cytoplasm. In several IMT 
cases, ALK is fused to RANBP2 and acquires a 
perinuclear localization. These cases generally have 
a more aggressive clinical course, suggesting that the 
RANBP2-dependent ALK perinuclear localization 
may be prognostic of malignant behavior.  
The first two IMT cases with a RANBP2-ALK 
fusion were described by Ma et al. (2003). By 
sequence analysis, the N-terminal 867 residues of 
RANBP2 were fused to the cytoplasmic segment of 
ALK, originating an 1430-amino acid chimeric 
protein. In both cases, the RANBP2-ALK fusion was 
present in myofibroblasts and was nuclear 
membrane-associated, attributable to the presence of 
the NPC-binding domain of RANBP2 in the fusion. 
Patel et al. (2007) reported on an IMT in a young boy 
(karyotype 
45,XY,der(2)inv(2)(p23q12)del(2)(p11.1p11.2),-
22) with an ALK-RANBP2 fusion, identified by 
FISH and confirmed by cloning and sequencing of 
the breakpoints.  
Chen and Lee (2008) described a hepatic IMT with 
a RANBP2-ALK rearrangement. PCR product 
sequencing revealed the presence of exon 18 from 
RANBP2 and exon 20 from ALK. Tumor cells 
showed a round cell phenotype with nuclear 
membrane accumulation of ALK protein. Mariño-
Enríquez et al. (2011) characterized 11 cases of intra-
abdominal IMT with epithelioid morphology. Nine 
showed perinuclear ALK staining, three of which 
harbored a RANBP2-ALK fusion. These patients 
experienced rapid recurrence. The authors suggest 
that the epithelioid variant of IMT with nuclear 
membrane or perinuclear ALK represents an 
aggressive form of sarcoma, with rapid recurrences 
and frequently fatal. Li et al. (2013) reported two 
more cases of IMT with RANBP2-ALK fusions, 
with epithelioid and rounded tumor cell morphology, 
from the pelvic and peritoneal cavities respectively, 
both associated with quick recurrence and poor 
prognosis. In 2014 the first case of a large tumor 
appearing in the pleural cavity was described (Kozu 
et al., 2014) in a patient with  
massive pleural effusion. The tumor showed the 
presence of a RANBP2-ALK fusion, rounded cells 
with an epithelioid shape, and a prominent 
inflammatory infiltrate, which led the authors to 
diagnose an epithelioid inflammatory 
myofibroblastic sarcoma (EIMS) and recognize it as 
an IMT variant.  
An EIMS case arising in the pelvic cavity was also 
described by Kimbara et al. (2014) as an aggressive 
variant of IMT.  
The tumor cells displayed epithelioid morphology 
and ALK staining on the nuclear membrane, 
associated with RANBP2-ALK fusion identified by 
RT-PCR.  
The patient experienced rapid local recurrence after 
surgery. The tumor was resistant to doxorubicin, but 
underwent shrinkage after treatment with the ALK 
inhibitor crizotinib. 
Multiple myeloma 
Note 
Felix et al. (2009) generated SAGE libraries from 
normal and neoplastic plasma cells to identify 
differentially expressed genes in multiple myeloma 
(MM). They identified 46 upregulated genes in the 
MM library and validated them by qRT-PCR. 
RANBP2 belongs to a group of upregulated genes in 
>50% of tested MM cases and in meta-analyses 
(ONCOMINE database) of MM compared to normal 
plasma cells. The authors proposed that RANBP2 
might be a potential therapeutic target in myeloma. 
Acute myelomonocytic leukemia 
Note 
Maesako et al. (2014) identified a RANBP2-ALK 
fusion mRNA transcript in a case of myeloid 
leukemia, associated with the chromosomal 
inversion inv(2)(p23q13), and resulting in nuclear 
membrane association of ALK. Another 
rearrangement involving RANBP2 and ALK was 
reported by Lim et al. (2014) in an acute 
myelomonocytic leukemia (AML) in a 31-year-old 
woman with a karyotype of 45,XX,inv(2)(p23q21),-
7[20], associated with a RANBP2-ALK fusion 
transcript and strong staining of the fusion protein 
around the nuclear membrane in leukemic cells. The 
patient had an unfavorable clinical course. 
Colorectal cancer 
Note 
Gylfe et al. (2013) highlighted another type of 
recombination tumorigenic events involving 
RANBP2.  
Because microsatellite instability occurs in some 
15% of all colorectal cancers, the authors sequenced 
the exomes of 25 colorectal tumors and respective 
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healthy colon tissue. They confirmed potential 
mutation hot spots in 15 genes, among which 
RANBP2; these were validated in tumors with 
microsatellite instability and showed that RANBP2 
also contains hot spot mutations in the validation set. 
Proposed tumor-promoting 
mechanisms of RANBP2 via SUMO-
conjugation and stimulation of 
tumorigenic signaling 
Note 
The data discussed above indicate some major routes 
through which RANBP2 can contribute to cancer 
onset and progression: increasing their genetic 
instability during mitosis and impairing global 
nuclear functions in interphase. An increasing 
implication of SUMO conjugation in the function of 
proteins relevant to cancer is emerging, particularly 
in DNA damage and repair.  
Among the growing instances of RANBP2-
dependent protein SUMOylation, some proteins 
have established roles in tumorigenic signaling 
pathways.  
Miyauchi et al. (2012) demonstrated a role of 
RANBP2 in SUMOylation and localization of 
MDM2, a major regulator of p53 stability, 
suggesting therefore a possible indirect implication 
of RANBP2 in p53 functions.  
Packham et al. (2014) showed that RANBP2 is 
implicated in the pro-tumorigenic activity of the 
insulin-like growth factor-1 receptor (IGF-1R), an 
activator of the PI3K/Akt pathway with key roles in 
tumorigenesis.  
The biological activity of IGF-1R depends on its 
nuclear translocation, which in turn depends on 
SUMOylation. Packham et al. (2014) characterized 
spatially regulated interactions of IGF-1R, first with 
dynactin, which transports IGF-1R to NPCs, and 
therein with importin-β and RANBP2. RANBP2 
interacts with and stabilizes sumoylated IGF-1R, 
enabling its nuclear accumulation and hence the 
activation of tumorigenic pathways that depend on 
it. Interestingly, RANBP2 levels are abnormally 
elevated in transgenic mouse models of prostate 
cancer constitutively expressing a PI3K catalytic 
subunit (PIK3CA), and treating the animals with a 
PI3K inhibitor decreases RANBP2 protein 
abundance (Renner et al., 2007).  
These data converge to suggest functional cross-
talks between RANBP2 and tumorigenic pathways. 
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